3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Myelodysplastic Syndromes
4
Leukemia, Myeloid, Acute
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neuroblastoma
3
Lymphoma, Large B-Cell, Diffuse
3
Recurrence
2
Neoplasms, Germ Cell and Embryonal
2
Multiple Myeloma
2
Lymphoma, Follicular
2
Lymphoma
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia
2
Hepatoblastoma
2
Glioblastoma
2
Breast Neoplasms
2
Brain Neoplasms
2
Anemia, Refractory, with Excess of Blasts
2
Wilms Tumor
1
Uveal Melanoma
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Primary Malignant Peripheral Nerve Sheath Tumors
1
Ototoxicity
1
Oligodendroglioma
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
Vincristine
13
Temozolomide
12
Cyclophosphamide
11
Irinotecan
8
Magnetic Resonance Spectroscopy
7
X-Rays
6
Vinorelbine
6
Specimen Handling
6
Phantoms, Imaging
6
Dactinomycin
6
Biopsy
5
fludarabine
4
Radiotherapy
4
Radiation
4
Nuclear Medicine Department, Hospital
4
Filgrastim
4
Etoposide
4
pegfilgrastim
3
irinotecan sucrosofate
3
Sirolimus
3
Proton Therapy
3
Melphalan
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rhabdomyosarcoma
×
Vorinostat
×
1 year
×
Clear all
NCT04308330
2026-04-15
NYMC195
New York Medical College
Phase 1
Recruiting
30 enrolled